ReiThera Expands Viral Vector Production Capabilities with Opening of New Manufacturing Facility

Published on: 

The new facility will allow ReiThera to consolidate its competitive position as a leading CDMO specialized in viral vector production.

ReiThera announced on Nov. 3, 2022 that it has received operational authorization from the Italian Medicines Agency (AIFA) to open the new production area at its new facility at the Castel Romano Technopole. The 1500-m2 facility will focus on the large-scale production of viral vectors for vaccines and gene therapy.

The new facility will serve as ReiThera’s client base and offer maximum flexibility in processing scale, able to accommodate good manufacturing practice productions based on adenovirus, adeno-associated virus, and lentivirus. The construction of the facility began in May 2020 with an investment of more than 15 million euros by ReiThera.

“Thanks to the operational authorization of this expanded facility, the ReiThera team, which combines high-level scientific knowledge with extensive experience in the engineering and bioprocessing of viral vectors, will be able to support companies engaged in the development of products in the field of vaccines and advanced therapies, from the fine-tuning of small-scale production processes to production on a commercial scale,” said StefanoColloca, chief technology officer and co-founder of ReiThera, in a company press release.


Source: ReiThera